What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?-Reference-Cited by-同舟云学术

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?

Published:2023-12-05 Issue:1 Volume:24 Page:
ISSN:1129-2377
Container-title:The Journal of Headache and Pain
language:en
Short-container-title:J Headache Pain

Author:

Waliszewska-Prosół Marta,Vuralli Doga,Martelletti Paolo

Abstract

AbstractIn this editorial we aim to provide potential therapeutic options in patients who do not benefit from treatment with CGRP(r) monoclonal antibodies. Based on current real-life studies and analysis of practical and economic aspects, we will analyze the potential benefits of changing CGRP-targeted treatment.

Publisher

Springer Science and Business Media LLC

Subject

Anesthesiology and Pain Medicine,Neurology (clinical),General Medicine

Link

https://link.springer.com/content/pdf/10.1186/s10194-023-01698-8.pdf

Reference42 articles.

1. Edvinsson L (2022) Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-successful translation of basic science to clinical practice. J Intern Med 292:575–586

2. Russo AF, Hay DL. CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond. Physiol Rev. 2023;103(2):1565–644.

3. Sacco S, Amin FM, Ashina M, Bendtsen L, Deligianni CI, Gil-Gouveia R, Katsarava Z, MaassenVanDenBrink A, Martelletti P, Mitsikostas DD, Ornello R, Reuter U, Sanchez-Del-Rio M, Sinclair AJ, Terwindt G, Uluduz D, Versijpt J, Lampl C (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention – 2022 update. J Headache Pain 11(1):67

4. Fiedler-Kelly J, Passarell J, Ludwig E et al (2020) Effect of fremanezumab monthly and quarterly doses on efficacy responses. Headache 60(7):1376–1391

5. Ashina M (2020) Migraine. N Engl J Med 383(19):1866–1876

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine;Expert Review of Neurotherapeutics;2024-09-12

2. Neuromodulation treatments for migraine: a contemporary update;Current Opinion in Anaesthesiology;2024-07-08

3. Switching CGRP(r) MoAbs in migraine: what evidence?;Expert Opinion on Biological Therapy;2024-05-03